On 18 September the FDA granted Priority Review to the application for efzimfotase alfa, an investigational treatment from Alexion, AstraZeneca’s rare-disease unit, for patients aged two and older with hypophosphatasia. The designation shortens the review goal; the PDUFA date is anticipated in the first half of 2027. It is not a marketing authorisation.

Hypophosphatasia is a rare metabolic disease with insufficient alkaline-phosphatase activity, which matters for mineralising bone and teeth. The picture ranges from dental problems and pain to fractures, weakness and severe complications.

The file rests on the Phase III programme HICKORY, MULBERRY and CHESTNUT. The company calls it the largest Phase III programme for the condition. That claim is the manufacturer’s, not an FDA verdict.

Priority Review means the agency treats the application as potentially important relative to existing options. It does not confirm final efficacy, guarantee approval or replace a safety review. If approved, the exact indication will sit on the FDA label.

Patients should not change current treatment on the basis of the announcement. STRENSIQ (asfotase alfa) remains the authorised therapy for certain forms; efzimfotase alfa is still investigational.

This article distinguishes review priority from authorisation. It is not medical advice.

The picture is a laboratory or institutional frame, not an identifiable patient and not a box of an approved medicine.

Image: FDA White Oak campus, Building 66 / Wikimedia Commons, public domain (FDA). The campus, not efzimfotase alfa authorisation. Cropped to 16:9.

Source consulted: AstraZeneca US — Efzimfotase alfa granted Priority Review in the US; FDA — Priority Review.